Erin Campbell

The Council of Canadian Innovators (CCI) is engaging with government officials to discuss the alignment between CCI’s priorities and the federal government’s efforts to foster innovation in Canada. These discussions focus on ensuring that government programs and policies effectively support high-growth Canadian technology firms and strengthen the country’s innovation ecosystem. Canadian Sovereign AI Compute Strategy: advocacy was focused on bringing domestic firms into the value chain through policies and measures that provide equal opportunity for Canadian Head Quartered companies. Discussion on the intangible economy, SR&ED, and economic growth as it relates to domestic expenditures for intellectual property filing, as well as a focus on small and medium-sized companies. US Trade - discussed Tariffs and handling of Canada US Mexico Trade Agreement. Sustainable Development Technology Canada (SDTC) to establish a sponsorship agreement related to CCI's Board education training program for the intangible economy. Small Business and Tourism, Changes to Canadian Export Program (CanExport) so it allows more technology companies to apply Procurement – Changes to Request for Proposal (RFP) process to break down large bundles into smaller amounts for Medium and Small Business (SMEs) can apply Health Canada: advocate for an increase of resources for Therapeutics Canada for them to speed up processing times and efficiencies within their department; create working groups and framework with industry leaders and health Canada on digital and data health, and create a therapeutics working group with industry and health Canada. Finance – Changes to Scientific research and experimental development (SR&ED) tax incentive program to make the process easier for Medium and Small Business (SMEs) to apply and report on the current program, to further increase the maximum a SME can apply for Export Development Canada (EDC) to establish a sponsorship agreement related to CCI's Board education training program for the intangible economy. Environment and Climate Change Canada, give input and feedback on the PanCanada Framework, Canada-China agreement for scientific and technological cooperation, and the relationship between Carbon Dioxide (CO2) Emitters & CO2 Reducers. Our focus is on involving Canadian high-growth firms in the policies and programs the government is working on regarding climate change and the greening of government. Discussions on international trade, specifically on the North American Free Trade Agreement with respect to data localisation, labour mobility and tariffs. Defence & Security: advocate for a domestic-focused cybersecurity ecosystem that has Canadian companies at the centre of a national cybersecurity defence policy. Citizenship and immigration – Change the current work visa time lines, seek changes to the the Labour Market Impact Assessment for expatiating and a faster process Changes to Industrial Research Assistance Program (IRAP) to make the process easier for Medium and Small Business (SMEs) to apply and report on the current program, to Increase the maximum amount a SME can apply for Canada Revenue Agency (CRA) - changes to (scientific research and experimental development) SR&ED program with how it is administered and reviewed. Discussed companies SR&ED claims and issues with their processing. Business Development Bank of Canada (BDC) to establish a sponsorship agreement related to CCI's Board education training program for the intangible economy.

C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program. The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry. Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry. Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention. Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.

Innovation policy and programming related to Mitacs domestic and international activity, including the Mitacs Globalink program and efforts to attract top talent and researchers to Canada. Funding to support ongoing growth in work-integrated learning collaborations between industry and academia in relation to Mitacs programs. Funding and policy development to support industry-academic research and development partnerships, commercialization, job creation, training and professional skills development for post-secondary students and post-doctoral fellows, international research collaborations and the promotion of activities that support innovation in Canada.

Policies aimed at reinforcing pharmaceutical supply chain. Discussion regarding the launch of new branded product in the rare disease space Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development. Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project. Policies aimed at facilitating generic drug repurposing. Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products. Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.